EP0249618A1 - Mischungen von tumor-nekrose-faktoren mit antibiotika und verfahren zur behandlung von tumoren - Google Patents

Mischungen von tumor-nekrose-faktoren mit antibiotika und verfahren zur behandlung von tumoren

Info

Publication number
EP0249618A1
EP0249618A1 EP19870900104 EP87900104A EP0249618A1 EP 0249618 A1 EP0249618 A1 EP 0249618A1 EP 19870900104 EP19870900104 EP 19870900104 EP 87900104 A EP87900104 A EP 87900104A EP 0249618 A1 EP0249618 A1 EP 0249618A1
Authority
EP
European Patent Office
Prior art keywords
tnf
antibiotics
combinations
antibiotic
chloramphenicol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19870900104
Other languages
English (en)
French (fr)
Inventor
Walter Charles Fiers
Lucia Marie Fransen
Jose Van Der Heyden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen NV
Original Assignee
Biogen NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen NV filed Critical Biogen NV
Publication of EP0249618A1 publication Critical patent/EP0249618A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta

Definitions

  • This invention relates to combinations useful for the enhancement of growth inhibition or killing of tumor cells. More particularly, this invention relates to combinations of natural or recombinant tumor necrosis factors ("TNF”) and broad spectrum antibiotics, such as chloramphenicol and tetracycline, which impede or inhibit protein syn ⁇ thesis in the mitochondria of the target cell. Accord ⁇ ing to this invention, these antibiotics are used to enhance the growth inhibiting or killing effect of TNFs on tumor cells.
  • TNF tumor necrosis factors
  • broad spectrum antibiotics such as chloramphenicol and tetracycline
  • TNF is produced by macrophages and mono- nuclear phagocytes. It is cytotoxic or cytostatic for a broad range of animal and human cancer cells in vitro and induces hemorrhagic necrosis in certain animal tumors and heterotransplanted human tumors in vivo [K. Haranaka and N. Satomi, "Note: Cytotoxic Activity of Tumor Necrosis Factor (TNF) on Human Cancer Cells in vitro, " Japan J. Exp. Med. , 51, pp. 191-94 (1981); L. Old, "Cancer Immunology: The -2-
  • Antibiotic agents may be classified on the basis of their chemical structure and mechanism of action. For example, agents that affect the function of ribosomes to inhibit or impede mitochondrial protein synthesis form a class of antibiotics which are useful in the combinations of this invention. This class includes chloramphenicols and tetracy- clines, aminoglycosidic antibiotics, the macrolide antibiotics (i.e., erythromycin), linco ycin, and its congener clindamycin.
  • Tetracyclines comprise a class of broad- spectrum antibiotics with a wide-range of anti- microbial activity. They are metabolites or semi- synthetic derivatives of metabolites of Streptomyces aureofaciens. They have bacteriostatic, or, at high concentrations, bacteriocidal effects on many species of gram-positive and gram-negative bacteria, spiro- chetes, and rickettsiae.
  • the site of action of tetracyclines is the ribosome. They inhibit protein synthesis by preventing the addition of amino acids to a growing peptide chain. Tetracyclines also impair protein synthesis in mammalian cells at high concen- trations [A. Goodman et al., The Pharmacological
  • Chloramphenicol is an antibiotic produced by Streptomyces venezuelae. It is a broad spectrum antibiotic which also inhibits protein synthesis in bacteria by binding to the ribosomes of its target. Chloramphenicol can also inhibit mitochondrial protein synthesis in mammalian cells probably because mito ⁇ chondrial ribosomes resemble bacterial ribosomes [L. . Wheeldon and A. L. Lehninger, Biochemistry, 5, pp. 3533-45 (1966)]. -3-
  • the a inoglycoside antibiotics include gentamicin, tobramycin, amikacin, kanamycin, strepto ⁇ mycin and neomycin. These antibiotics act directly on the ribosome, where they inhibit protein synthesis and decrease the fidelity of translation of the genetic code [Goodman and Gil an's, supra, pp. 1162-80].
  • Erythromycin and other macrolide anti ⁇ biotics, lincomycin, and clindamy ⁇ in inhibit protein synthesis by binding to 50S ribosomal subunits.
  • erythro ⁇ mycin, chloramphenicol and clindamycin can interfere with each other's binding at this site [Goodman and Gilman's, supra, pp. 1222-27].
  • Conventional treatment of tumors include non-surgical treatments, such as chemotherapy and radiation, and surgical treatments. Typically, these treatments are characterized by various undesirable side effects. Non-surgical treatments having immuno- suppressant effects may increase the patient's susceptibility to secondary infections. Surgical treatments to excise transformed cells involve risks attendant with invasive procedures and may not effec ⁇ tively remove or eliminate the entire transformed cell population.
  • Alternative methods of treatment for cancers and non-malignant tumors have involved the use of monoclonal antibodies to tumor specific antigens on the surface of transformed cells.
  • various therapies have been directed to aug- - — meriting the body's immune response to tumorigenic cells by increasing the body's level of various lymphokines.
  • TNF alone is known to inhibit the growth of or to kill tumor cells.
  • combinations of human lymphotoxin and human gamma interferon have been reported to inhibit tumor growth [European patent application 128,009].
  • Combi ⁇ nations of TNF and human interferon have also been reported to demonstrate a greater growth inhibitory or cytotoxic effect on human tumors than the sum of their separate effects [L.
  • the present invention provides combinations and methods that cause the inhibition of tumor growth or the enhancement of tumor cell death to a far greater degree than TNF alone.
  • broad spectrum anti ⁇ biotics which inhibit or impede protein synthesis in the target cell dramatically enhance the tumoricidal effect of TNF.
  • Particularly useful combinations with such TNF treatments include the tetracyclines or chloramphenicol.
  • TNF tumor necrosis factor
  • TNF is a growth inhibitory or cytotoxic lymphokine. Natural TNF is a protein with a molecular weight of over 17,000. TNF has been produced in small quantities in vivo. For example, endotoxin may be used to trigger the release of TNF by activated macrophages. TNF can also be induced in established cell lines, i.e., U937 [D. J. Camerson, Reticuloenthel. Soc. , 34, pp. 45-52 (1983)]. TNF has been cloned and expressed in various host-vector systems [A. L. Mar enout et al., "Molecular Cloning And Expression Of Human Tumor Necrosis Factor And Com- parison With Mouse Tumor Necrosis Factor, " Eur. J.
  • TNF includes all proteins, polypeptides, and peptides which are natural or recombinant TNFs, or derivatives thereof, and which are characterized by the tumoricidal activity of these TNFs. They include TNF-like com- pounds from a variety of sources, such as natural TNFs, recombinant TNFs, and synthetic or semi-syn ⁇ thetic TNFs.
  • Tumor encompasses any undesirable proliferation of cells. Such proliferation includes malignant and non-malignant, solid or fluid tumors, carcinomas, -6- myelomas, sarcomas, leukemias, lymphomas,. and other cancerous, neoplastic, or tumorigenie diseases.
  • Chloramphenicol is an antibiotic which impedes protein synthesis in bacteria and mammalian cells by attaching to bacterial ribo ⁇ somes or mitochondrial ribosomes, respectively, in order to cause cell death.
  • chloramphenicol includes related derivatives, such as thioamphenicol, a more water-soluble and less toxic derivative of chloramphenicol.
  • Tetracycline Tetracyclines are a class of antibiotics which impede protein synthesis in bacteria and mammalian cells by attaching to bacterial ribosomes or mitochondrial ribosomes, respectively, in order to cause cell death.
  • tetracycline includes related members of the broad family of antibiotics generally known as tetracycline, as well as their derivatives. The term includes, for example, chlortetracycline, oxy- tetracycline, demeclocycline, methacycline, doxycycline and minocycline.
  • This invention relates to combinations and methods for treating tumors and neoplastic diseases. More particularly, this invention relates to combi- nations of pharmaceutically effective amounts of TNF and pharmaceutically effective amounts of broad spectrum antibiotics that inhibit or impede protein synthesis in the target cell.
  • those antibiotics are selected from the group of tetracyclines or chloramphenicol.
  • TNFs useful in the combinations and treatments of this invention are the TNFs produced in vitro by a variety of cells in response to various inducers.
  • these TNFs include compounds displaying TNF activity obtained from sera of mice -7- and rabbits which have been infected with Bacillus- Cal ette-Guerin (BCG) or Corynebacterium and treated with lipopolysaccharide (LPS) of Escherichia coli [E. A. Carswell et al., "An Endotoxin-Induced Serum Factor That Causes Necrosis Of Tumors", Proc. Natl. Acad. Sci. USA, 72, pp. 3666-70 (1975)].
  • BCG Bacillus- Cal ette-Guerin
  • LPS lipopolysaccharide
  • human monocytes isolated from the blood of healthy human donors, and stimulated with lymphokines or LPS produce chemical agents having cytotoxic or cytostatic effects on mouse target cells and human transformed cells which are useful in the compositions of this invention
  • lymphokines or LPS produce chemical agents having cytotoxic or cytostatic effects on mouse target cells and human transformed cells which are useful in the compositions of this invention
  • TNFs useful in the combinations and treat ⁇ ments of this invention may also be produced and purified in large amounts using recombinant DNA tech ⁇ nology [L. Fransen et al., "Molecular Cloning Of Mouse Tumour Necrosis Factor cDNA And Its Eukaryotic Expres ⁇ sion," Nucl. Acid Res. , 13, pp. 4417 et seq. (1985); A. L. Marmenout et al., "Molecular Cloning And Expres- sion Of Human Tumor Necrosis Factor And Comparison With Mouse Tumor Necrosis Factor," Eur. J. Biochem, 152, pp. 515-22 (1985); see also D. Pennica et al., Nature, 312, pp. 724-28 (1984); T. Shirai, Nature, 313, pp. 803-06 (1985); A. M. Wang et al., Science, 228, pp. 149-54 (1985)].
  • TNFs derived from the target species are preferably used.
  • TNFs derived from other species may be used in the combinations and treatments of this invention if they are active in the target cells.
  • mouse TNF has been shown to be active in human cell lines in vitro.
  • mammals are treated with pharmaceutically effective amounts of the two active components — TNF and a broad spectrum antibiotic — of the combinations of this invention for a period of time sufficient to suppress tumor growth, and preferably to kill tumor cells.
  • the mammals are treated with a composition comprising a combination of TNF and a broad spectrum antibiotic which impedes or inhibits ribosomal protein synthesis.
  • they are treated sequentially with the two components.
  • the particular sequence of treatment chosen does not appear to be important.
  • mammals may be treated with sub ⁇ cutaneous, intravenous or intramuscular injections of TNF of between about 10 ⁇ g to 100 mg per patient per day.
  • this dosage should be adjusted by the treating physician according to recognized medical standards, to accommodate the physical condition and acceptance level of the patient.
  • they are also treated with a pharmaceutically effective amount of a broad spectrum antibiotic before, concurrently, of after treatment with TNF. Most commonly, the antibiotic is administered orally, its dosage being the standard one used against infection. [See Goodman and Gilman's, supra, pp. 1185, 1193 and 1222-27.] -10-
  • Table I depicts the use of the combinations of this invention. More particularly, it shows the effect of recombinant TNF in combination with chlor ⁇ amphenicol, thioamphenicol (a more water-soluble and less toxic derivative of chloramphenicol) and tetra ⁇ cycline, on the B16B16, PG19 and Friend leukemia 745 cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP19870900104 1985-12-05 1986-12-05 Mischungen von tumor-nekrose-faktoren mit antibiotika und verfahren zur behandlung von tumoren Withdrawn EP0249618A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80585385A 1985-12-05 1985-12-05
US805853 1985-12-05

Publications (1)

Publication Number Publication Date
EP0249618A1 true EP0249618A1 (de) 1987-12-23

Family

ID=25192688

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19870900104 Withdrawn EP0249618A1 (de) 1985-12-05 1986-12-05 Mischungen von tumor-nekrose-faktoren mit antibiotika und verfahren zur behandlung von tumoren

Country Status (3)

Country Link
EP (1) EP0249618A1 (de)
JP (1) JPS63501724A (de)
WO (1) WO1987003489A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2638652B2 (ja) * 1988-07-18 1997-08-06 カイロン・コーポレーション カケクチンと反応するモノクロナール抗体
DE3907244A1 (de) * 1989-03-07 1990-09-13 Knoll Ag Erzeugnisse, enthaltend ein lithiumsalz und einen tumor-nekrose-faktor
CA2064915C (en) 1989-08-07 2001-05-29 Deborah A. Rathjen Tumour necrosis factor binding ligands
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
AU634768B2 (en) * 1990-04-07 1993-03-04 Abbott Gmbh & Co. Kg Products containing a lithium salt and a tumour necrosis factor
JP4770313B2 (ja) * 2005-07-27 2011-09-14 ソニー株式会社 オーディオ信号の生成装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019719A (ja) * 1983-07-15 1985-01-31 Asahi Chem Ind Co Ltd 抗腫瘍活性を有する蛋白質
DE3472793D1 (en) * 1983-12-26 1988-08-25 Asahi Chemical Ind A novel physiologically active polypeptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8703489A1 *

Also Published As

Publication number Publication date
JPS63501724A (ja) 1988-07-14
WO1987003489A1 (en) 1987-06-18

Similar Documents

Publication Publication Date Title
JP4929341B2 (ja) インターロイキン−１０生成を増進するためのテトラサイクリン化合物の使用方法
JPS62249929A (ja) リンホカインを含む感染治療剤
EP0259863B1 (de) Zusammensetzungen zur Modulation der Effekten von TNF und IL-1
IE901297L (en) Use of cytokines for treating preneoplastic lesions
van der Meer The effects of recombinant interleukin-1 and recombinant tumor necrosis factor on non-specific resistance to infection
Kalechman et al. Radioprotective effects of the immunomodulator AS101.
JPH03501382A (ja) 組換えコロニー刺激因子‐１の使用
EP0249618A1 (de) Mischungen von tumor-nekrose-faktoren mit antibiotika und verfahren zur behandlung von tumoren
US4857314A (en) C-reactive proteins in treatment of animal and human cancers
US5250296A (en) Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
JPH0813756B2 (ja) 細胞増殖抑制作用または細胞毒作用を有する治療用活性物質の組合せ
EP0527852B2 (de) Verfahren und zubereitungen für die behandlung von verletzungen
Maekawa et al. Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563
Davidkova et al. Endogenous production of tumor necrosis factor in normal mice orally treated with DEODAN—a preparation from Lactobacillus bulgaricus “LB51”
Bahnson et al. In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2)
Kuttan Tumoricidal activity of mouse peritoneal macrophages treated with Viscum album extract
Ben-Nathan et al. The protective effect of melatonin in viral and bacterial infections
Parant Influence of synthetic adjuvants on nonspecific resistance to infections
JPS5995220A (ja) 免疫療法剤
Tyring et al. Eradication of cultured human melanoma cells by immune interferon and leukocytes
Labro The prohost effect of antimicrobial agents as a predictor of clinical outcome
Lasek et al. Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice
Tamura et al. Evaluation of recombinant human tumor necrosis factor by scheduled intratumoral administration in mice bearing transplantable tumors
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
EP0405463A2 (de) Antikrebstherapie-Verbesserungsmittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19870817

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19890704

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FRANSEN, LUCIA, MARIE

Inventor name: VAN DER HEYDEN, JOSE

Inventor name: FIERS, WALTER, CHARLES